BioCentury | Jul 19, 2019
Tools & Techniques

A mark up for RNA epigenetics

As a field, RNA epigenetics is still in its infancy, though picking up pace as researchers translate lab findings to drug development. Two papers straddling academia and industry provide a new quantitative method that can...
BioCentury | Feb 1, 2017
Clinical News

Emixustat: Ph IIa started

Kubota’s Acucela Inc. subsidiary began a blinded, U.S. Phase IIa trial to evaluate 2.5, 5 and 10 mg oral emixustat once daily for 1 month in about 30 patients. Kubota Pharmaceutical Holdings Co. Ltd. (Tokyo:4596),...
BioCentury | Jun 20, 2016
Company News

Otsuka Pharmaceutical, Acucela deal

Otsuka terminated deals with Acucela to co-develop and co-commercialize Acucela’s emixustat ( ACU-4429 ) and Otsuka’s OPA-6566 . The emixustat deal was signed in 2008 and granted Otsuka co-development rights in North America and exclusive rights in Asia....
BioCentury | Jun 15, 2016
Company News

Acucela slides after Otsuka ends ophthalmic deals

Acucela Inc. (Tokyo:4589) sank Y400 (24%) to Y1,253 on Tuesday after it said Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) terminated co-development deals for Acucela's emixustat (formerly ACU-4429 ) and Otsuka's OPA-6566 . Last month, Acucela said emixustat...
BioCentury | May 30, 2016
Clinical News

Emixustat: Phase IIb/III data

Top-line data from the double-blind, U.S. Phase IIb/III S.E.A.T.T.L.E. trial in 508 patients with GA secondary to dry age-related AMD showed that once-daily 2.5, 5 and 10 mg oral emixustat each missed the primary endpoint...
BioCentury | May 27, 2016
Clinical News

Acucela's emixustat fails in AMD study

Acucela Inc. (Tokyo:4589) dropped Y1,000 (17%) to Y4,790 after it said emixustat (formerly ACU-4429 ) missed the primary endpoint of the Phase IIb/III S.E.A.T.T.L.E. study to treat geographic atrophy (GA) in patients with age-related macular degeneration....
BioCentury | May 16, 2016
Clinical News

Emixustat: Phase II started

Acucela began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate once-daily oral emixustat for 12 weeks in 20 patients. Doses of emixustat will be doubled each week until week 4, after which patients will...
BioCentury | Jun 8, 2015
Clinical News

Emixustat: Phase IIa data

The double-blind, U.S. Phase IIa 4429-201 trial in 72 patients with GA associated with dry AMD showed that emixustat suppressed the recovery of rod photoreceptor responses from baseline to day 14 by 26.3% at the...
BioCentury | Jun 5, 2015
Clinical News

Acucela gains on Phase II emixustat data

Acucela Inc. (Tokyo:4589) gained Y45 to Y740 after emixustat ( ACU-4429 ) demonstrated dose-dependent and reversible suppression of rod photoreceptor sensitivity in a Phase IIa trial to treat geographic atrophy (GA) associated with dry age-related macular degeneration...
BioCentury | Mar 10, 2014
Clinical News

Emixustat: Completed Phase IIb/III enrollment

Acucela completed enrollment of 508 patients in the double-blind, placebo-controlled Phase IIb/III SEATTLE trial evaluating 2.5, 5 and 10 mg oral emixustat once daily for 24 months. The product has Fast Track designation in the...
Items per page:
1 - 10 of 76